Online inquiry

IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12079MR)

This product GTTS-WQ12079MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12079MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12666MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ10237MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ12845MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ3734MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ12474MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ9785MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ817MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ13518MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRX002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW